» Articles » PMID: 34091353

Sex Differences in Off-target Binding Using Tau Positron Emission Tomography

Overview
Journal Neuroimage Clin
Publisher Elsevier
Specialties Neurology
Radiology
Date 2021 Jun 6
PMID 34091353
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Off-target binding in the skull and meninges is observed in some subjects undergoing tau positron emission tomography (PET) and could potentially differ between men and women. In this study we elucidate sex differences in tau off-target binding using three different tau PET tracers.

Methods: 541 cognitively unimpaired amyloid-β negative participants underwent tau PET using [F]flortaucipir (n = 165), [F]RO948 (n = 189) and [F]MK6240 (n = 187). Baseline SUVR-values were compared between females and males at the voxel level and using a region-of-interest (ROI) encompassing the skull/meninges. In addition, we assessed the cross-sectional relationship between baseline skull/meninges SUVR and age and assessed change in skull/meningeal SUVR values over time in a subsample with longitudinal data (n = 63).

Results: Voxel-wise analysis showed higher meningeal off-target binding in women compared to men across all three tracers. The SUVRs in the skull/meningeal ROI were highest using [F]RO948, followed by [F]MK6240 and [F]flortaucipir (p < 0.001). For all tracers, females showed higher skull/meningeal ROI retention (mean SUVR ± SD [F]flortaucipir: 0.82 ± 0.14; [F]RO948: 1.26 ± 0.30; [F]MK6240: 1.09 ± 0.19) compared to men ([F]flortaucipir: 0.70 ± 0.11; [F]RO948: 1.10 ± 0.24; [F]MK6240: 0.97 ± 0.17) (p < 0.001). For [F]flortaucipir and [F]RO948, off-target binding in the skull/meninges decreased with age.

Conclusion: There is an effect of sex on off-target retention in the meninges/skull across [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers.

Citing Articles

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.

Coughlan G, Klinger H, Boyle R, Betthauser T, Binette A, Christenson L JAMA Neurol. 2025; .

PMID: 40029638 PMC: 11877413. DOI: 10.1001/jamaneurol.2025.0013.


Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.

Gogola A, Lopresti B, Minhas D, Lopez O, Cohen A, Villemagne V Geriatrics (Basel). 2025; 10(1).

PMID: 39997526 PMC: 11855481. DOI: 10.3390/geriatrics10010027.


Head-to-head comparison of tau PET tracers [F]PI-2620 and [F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort.

Tonietto M, Sotolongo-Grau O, Roe-Vellve N, Bullich S, Tartari J, Sanabria A Alzheimers Res Ther. 2024; 16(1):257.

PMID: 39605030 PMC: 11603960. DOI: 10.1186/s13195-024-01622-5.


Increased between-network connectivity: A risk factor for tau elevation and disease progression.

Hojjati S, Butler T, Luchsinger J, Benitez R, de Leon M, Nayak S Neurosci Lett. 2024; 840:137943.

PMID: 39153526 PMC: 11459384. DOI: 10.1016/j.neulet.2024.137943.


Explaining variability in early stages of [18F]-flortaucipir tau-PET binding: Focus on sex differences.

Bachmann D, Buchmann A, Studer S, Saake A, Rauen K, Gruber E Alzheimers Dement (Amst). 2024; 16(1):e12565.

PMID: 38463040 PMC: 10921068. DOI: 10.1002/dad2.12565.